Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nicolas Suter"'
Autor:
Fanny Zulay Acero Brand, Nicolas Suter, Jean-Philippe Adam, Bernard Faulques, Antonio Maietta, Denis Soulières, Normand Blais
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-5 (2018)
Abstract Background Pembrolizumab is an anti–programmed death 1 (PD-1) receptor monoclonal antibody that has shown activity as second line treatment for metastatic head and neck squamous cell carcinoma (HNSCC). Immune-related adverse events are now
Externí odkaz:
https://doaj.org/article/906f2eef5b94415eb43d511c972254a3
Autor:
Nicolas Suter, Madeleine Durand, Dane Christina Daoud, Bernard Faulques, Daniel von Renteln, Mickael Bouin
Publikováno v:
World Journal of Gastroenterology. 24:2518-2536
To compare endoscopic submucosal dissection (ESD) outcomes between Eastern and Western countries.A systematic review and meta-analysis was performed using PubMed, MEDLINE, Web of Science, CINAHL and EBM reviews to identify studies published between 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb3d2db373819ff353010fb1603c69a0
https://doi.org/10.3748/wjg.v24.i23.2518
https://doi.org/10.3748/wjg.v24.i23.2518
Autor:
Madeleine Durand, Mickael Bouin, Bernard Faulques, Dane Christina Daoud, Nicolas Suter, Alan N. Barkun, D von Renteln
BACKGROUND: Endoscopic submucosal dissection (ESD) has become the preferred approach to remove advanced gastrointestinal lesions in Asian countries while widespread adoption in the Western world remains limited. Studies evaluating differences for ESD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::508305fb07aef04e6614ce54d83a4075
https://europepmc.org/articles/PMC6508363/
https://europepmc.org/articles/PMC6508363/
Autor:
Normand Blais, Jean-Philippe Adam, Denis Soulières, Antonio Maietta, Nicolas Suter, Bernard Faulques, Fanny Zulay Acero Brand
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-5 (2018)
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-5 (2018)
Background Pembrolizumab is an anti–programmed death 1 (PD-1) receptor monoclonal antibody that has shown activity as second line treatment for metastatic head and neck squamous cell carcinoma (HNSCC). Immune-related adverse events are now well des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f325d711cdb45767c2da14075eaabde
https://pubmed.ncbi.nlm.nih.gov/29548299
https://pubmed.ncbi.nlm.nih.gov/29548299